Skip to content
    TSHA
    Earnings call· Jun 2026(Q2 FY26)

    Taysha Gene Therapies Q2 FY26 earnings call TSHA

    Aug 11, 2026 Source

    Executive summary

    Taysha Gene Therapies Q2 FY26 — Clinical Progress and Strengthened Financial Position

    Taysha Gene Therapies reported significant clinical and operational progress in Q2 FY26, completing dosing in both its pivotal REVEAL and ASPIRE trials for TSHA-102 in Rett syndrome. The company also strengthened its balance sheet with a $230 million financing, extending its cash runway into the second half of 2028. Payer research indicated strong support for TSHA-102's value proposition, driven by its transformative potential and convenient administration, reinforcing confidence in its commercial outlook despite an increase in net loss for the quarter.

    Highlights

    5

    • Dosing completed in REVEAL pivotal trial with 17 patients, exceeding the planned enrollment.

    • Dosing completed in ASPIRE trial with 4 patients, exceeding the planned enrollment.

    • REVEAL Part A data showed 100% response rate at 12 months in 12 patients, exceeding the FDA-aligned 33% minimum efficacy threshold.

    • Cash and cash equivalents of $455.4 million as of June 30, 2026, expected to fund operations into H2 2028.

    • Expanded partnership with Catalent for commercial manufacturing support of TSHA-102.

    Concerns

    2

    • Net loss for Q2 FY26 increased to $46.6 million, up from $26.9 million in Q2 FY25.

    • A single moderate Grade 2 treatment-related adverse event of peripheral sensory neuropathy occurred in 1 patient in the REVEAL pivotal trial, leading to overnight hospitalization and technical classification as a serious adverse event.

    Guidance & targets

    4
    CategoryTargetConfidence
    Cash runway
    Into the second half of 2028 and through potential BLA approval
    high materiality
    High
    BLA-enabling PPQ campaign completion
    Complete in the fourth quarter of 2026
    high materiality
    High
    Top-line data from REVEAL pivotal trial 6-month interim analysis
    Report in the first half of 2027
    high materiality
    High
    FDA feedback on BLA submission pathway
    Receive in the first half of 2027
    high materiality
    High

    Operational metrics

    15
    Research and development expenses
    $38.6Mvs $20.1M in Q2 FY25
    Q2 FY26
    General and administrative expenses
    $12.1Mvs $8.6M in Q2 FY25
    Q2 FY26
    Net loss
    $46.6Mvs $26.9M in Q2 FY25
    Q2 FY26
    Net loss per share
    $0.13vs $0.09 in Q2 FY25
    Q2 FY26
    Cash and cash equivalents
    $455.4M
    as of June 30, 2026

    Reflects gross proceeds of $230 million from June 2026 follow-on financing.

    Gross proceeds from follow-on financing
    $230M
    June 2026
    REVEAL pivotal trial patients dosed
    17over-enrolled
    to date

    Dosing completed in June 2026. Patients reflect broad age distribution (pediatric, adolescent, adult).

    ASPIRE trial patients dosed
    4
    to date

    Dosing completed in July 2026. Primarily safety-focused, designed to support broad label and provide insight into early intervention.

    Total patients treated with TSHA-102
    33
    to date

    As of August 2026 data cutoff, spanning broad range of ages, genotypes, and disease severities.

    Rett syndrome population older than 10 years of age
    over 85%
    prevalent population

    Highlights the commercial opportunity for TSHA-102 given consistent treatment effect regardless of age.

    Developmental milestones achieved (pediatric patients)
    16
    at 12 months and beyond

    Observed in REVEAL Part A data.

    Developmental milestones achieved (adolescent and adult patients)
    15
    at 12 months and beyond

    Observed in REVEAL Part A data.

    Total functional gains
    310
    at 12 months and beyond

    Includes developmental milestones and additional skills like enhanced motor skills, hand use, responding to questions, reduced seizure activity, and decreased hand stereotypies.

    Likelihood of gaining or regaining developmental milestone after 6 years of age
    less than 6.7%
    after 6 years of age

    Supports the minimum inclusion age of 6 years in the REVEAL pivotal trial and the meaningfulness of observed gains.

    Rett syndrome patients with history of seizures
    80% to 90%
    general population

    Highlights the prevalence of seizures in the Rett syndrome population.

    Industry KPIs

    5
    MetricValueDetails
    Launch access metricsStrong support for value proposition and reimbursement potential
    Pipeline read out calendarREVEAL pivotal 6-month interim analysis, FDA feedback on BLA pathway
    Regulatory approvals filingsBLA submission pathway discussions
    Clinical trial efficacy safety data100%%
    Cumulative patients uptake since launch33patients

    Deals & partnerships

    1
    CatalentExpanded partnership to include future commercial manufacturing support for TSHA-102.long-term

    Manufacturing will be conducted at Catalent's FDA-licensed gene therapy campus in Harmans, Maryland. Catalent will leverage its experience across more than 90 gene therapy programs.

    Risks & headwinds

    1
    Treatment-related adverse event (peripheral sensory neuropathy)Approximately 6 weeks after treatment

    Single moderate Grade 2 event, technically classified as serious adverse event due to overnight admission.

    Mitigation: Managed with immunomodulatory agents; patient discharged the following day with substantial recovery. Event is an expected AAV-associated risk and common in Rett syndrome patients. IDMC and FDA raised no concerns.

    What to watch in Q3 FY26

    4

    BLA-enabling PPQ campaign completion

    Q4 FY26
    CurrentOn track
    TargetCompletion in Q4 2026

    Why it matters

    This is a critical manufacturing milestone required for BLA submission.

    We remain on track to complete the BLA-enabling PPQ campaign in the fourth quarter of 2026.

    Q&A highlights

    5

    What specific feedback did payers provide regarding the one-time intrathecal (IT) administration procedure and outpatient setting, and how does this impact reimbursement discussions?

    Payers highly valued the transformative data and durability of TSHA-102, with the IT administration being seen as less invasive and attractive for outpatient reimbursement. This model allows for greater scalability and attractive margins for providers, reinforcing commercial potential.

    “The IT piece was something they definitely anchored to because of the fact that they realized that this is a much less invasive route of administration versus other ways to go direct to the CNS. They know that because of this administration aspect, that the reimbursement is going to be on the outpatient side, and so those are going to be attractive margins for those folks.”

    asked by Kristen Kluska · answered by Sean Nolan

    2 min read5 chapters

    Detailed Narrative

    01

    Clinical Trial Progress and Data Highlights

    Taysha completed dosing in both the REVEAL pivotal trial (17 patients) and the ASPIRE trial (4 patients), with both trials over-enrolled. The REVEAL Part A trial, with 12 patients having at least 12 months of follow-up, demonstrated a 100% response rate at 12 months based on FDA-aligned developmental milestone assessment criteria. This data supports the potential for an accelerated BLA submission based on 6-month interim analysis, which is expected in H1 2027.

    02

    Safety Profile of TSHA-102

    TSHA-102 continues to show a favorable and consistent safety profile across 33 patients treated over 3 years, with no severe treatment-related serious adverse events or dose-limiting toxicities. A single moderate Grade 2 peripheral sensory neuropathy event, an expected AAV-associated risk, occurred in one REVEAL pivotal trial patient. This event was managed with immunomodulatory agents, and the patient showed substantial recovery, with the IDMC and FDA raising no concerns.

    03

    Commercial Readiness and Payer Insights

    Payer market research demonstrated strong support for TSHA-102 due to its transformative disease-modifying potential and convenient one-time📎 intrathecal administration. Payers emphasized the importance of durable functional gains and improvements that translate into real-world benefits for patients and caregivers. The outpatient reimbursement model for intrathecal administration was also viewed as attractive, reinforcing confidence in the commercial potential and reimbursement outlook.

    04

    Manufacturing and Leadership Expansion

    Taysha expanded its partnership with Catalent for commercial manufacturing of TSHA-102, securing long-term capacity at an FDA-licensed AAV manufacturing facility. BLA-enabling process performance qualification (PPQ) activities are underway, with completion expected in Q4 2026. The company also strengthened its leadership team with the appointment of Mike Johannesen as Chief Legal Officer, bringing extensive gene therapy experience.

    05

    Scientific Foundation and Regulatory Strategy

    Data presented at the IRSF Rett Syndrome Scientific Meeting reinforced the clinical and scientific foundation of the TSHA-102 program. Analysis from natural history studies supported the design of the REVEAL pivotal trial, demonstrating a developmental plateau after 6 years of age. The Developmental Milestone Assessment (DMA) was psychometrically validated and supported by the FDA as a primary endpoint for single-arm interventional studies, strengthening confidence in the data integrity.

    AI-generated summary of the company’s earnings call. Not investment advice.